Frovatriptan and Menstrual Migraine

Study Overview
=================
Brief Summary
-----------------
We are looking for women who suffer from menstrual migraine to participate in a 2-visit migraine brain imaging research study. Our goal is to see how the menstrual migraine brain's pain pathways function when the migraineur has been taking Frovatriptan. During the screening visit (Visit 1) participants will sign the informed consent form, complete questionnaires, meet with the study physician, and have QST (quantitative sensory testing: to determine your pain thresholds for a heat stimulus) performed. For Visit 2's MRI scan, subjects will be asked to lie very still while the scan is occurring. In some parts, they will not have to do anything, while in others they will be asked to rate pain and unpleasantness for brush and thermal stimuli. Participants are compensated for both visits.

Official Title
-----------------
Mapping CNS Changes to Frovatriptan Administration in Acute Treatment of Prodrome or Preventative Treatment of Menstrual Migraine (MM)

Conditions
-----------------
Frovatriptan, Menstrual Migraine

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Regular Menstrual Phase Menstrual Migraine No significant medical history (Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc.) No significant medication history, except for migraine All patients will be currently taking or have previously taken triptan medications for migraine Weight, <285 pounds Not claustrophobic No contraindication to taking triptans Exclusion Criteria: Age <18 Significant medical problems (aside from pain before, during and after migraine episodes) Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.) Positive alcohol screen Women taking oral contraceptives Claustrophobia History of dermatological hypersensitivity in the facial area Positive history of cardiac problems/ abnormalities seen in EKG at initial screening visit Pregnancy Sensory loss detected on Quantitative Sensory Testing at screening Significant alcohol history (ingestion of 5 or more glasses (> 40 oz) of alcohol per week) Metal implants of any type (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, etc.) Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which could become heated up in the scanner, and potentially cause blistering or burning) Cardiac pacemakers Aneurysm clips and other vascular stents, filters, clips or other devices Prosthetic heart valves Other prostheses Neuro-stimulator devices Implanted infusion pumps Cochlear (ear) implants Ocular (eye) implants or known metal fragments in eyes Exposure to shrapnel or metal filings (sheet metal workers, welders, and others) Other metallic surgical hardware in vital areas Use of any of the following medications: Propanolol/ Inderol SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem, Symbyax, sertraline/ Zoloft, Fluvoxamine/ Luvox SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/ Maxalt, eletriptan/ Relpax, almotriptan/ Axert ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45, Sansert ketoconazole (Nizoral, Fungoral) itraconazole (Sporanox) ritonavir (Norvir) erythromycin (Erythrocin)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Frovatriptan<br>All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2). | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Menstrual Migraine, Frova, Imaging, fMRI, Pain